Peptide Initiative

Peptides · Peptide comparison

Exenatide vs Liraglutide

First-in-class GLP-1 receptor agonist derived from Gila monster venom (Byetta/Bydureon), FDA-approved for type 2 diabetes with demonstrated cardiovascular safety in the 14,752-patient EXSCEL trial and available in both twice-daily and once-weekly formulations

FDA-approved once-daily GLP-1 receptor agonist (Victoza/Saxenda) that reduces HbA1c by 0.9–1.6%, promotes 5–10% body weight loss, and demonstrated a 13% reduction in major adverse cardiovascular events in the landmark LEADER trial of 9,340 patients

  • Weight Management
  • Weight Management

At a glance

Quick comparison

Dose rangeExenatide10–10 mcgLiraglutide1.2–1.8 mg
FrequencyExenatideOnce weeklyLiraglutideOnce daily
AdministrationExenatideSubcutaneous injectionLiraglutideSubcutaneous injection
Cycle lengthExenatideOngoing/indefiniteLiraglutideOngoing/indefinite
Onset speedExenatideGradual (3-4 weeks)LiraglutideGradual (3-4 weeks)
Evidence levelExenatideStrong human trials (Phase 3 or FDA approved)LiraglutideStrong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Blood Sugar Control

Exenatide94%
LiraglutideNo recorded rating

Weight Loss

Exenatide86%
LiraglutideNo recorded rating

Heart Safety

Exenatide82%
LiraglutideNo recorded rating

Weight Management

ExenatideNo recorded rating
Liraglutide9%

Metabolic

ExenatideNo recorded rating
Liraglutide9%

Healing & Recovery

ExenatideNo recorded rating
Liraglutide8%

Technical data

Compound specifications

Exenatide

Molecular formula
C184H282N50O60S
Molecular weight
4,187 Da
Half-life
Byetta: ~2.4 hours (immediate-release); Bydureon: ~7 weeks effective duration via PLGA microsphere technology; Tmax ~2.1 hours (Byetta)
Bioavailability
65–75% after subcutaneous injection (Byetta); microsphere sustained release for Bydureon
CAS number
183321-74-6

Liraglutide

Molecular formula
C172H265N43O51
Molecular weight
3,751 Da
Half-life
~13 hours (enabling once-daily dosing); Tmax 8–12 hours; steady state in 3–5 days
Bioavailability
~55% after subcutaneous injection; >98% plasma protein binding to albumin via C16 fatty acid moiety
CAS number
204656-20-2

Protocols

Dosing compared

Exenatide

Subcutaneous

  • 5 mcgTwice daily, within 60 minutes before the two main meals · First 1 monthFDA-labeled starting dose for immediate-release Byetta to assess tolerability before escalating [6].
  • 10 mcgTwice daily, within 60 minutes before the two main meals · OngoingFDA-labeled maintenance dose for immediate-release Byetta after 1 month at the starting dose [6].
  • 2 mgOnce weekly · Ongoing chronic therapyExtended-release exenatide (Bydureon) FDA-labeled at 2 mg once every 7 days; convenient weekly alternative to twice-daily dosing [7]. Once-weekly exenatide has cardiovascular outcome data [1].

Liraglutide

Subcutaneous

  • Week 10.6 mgOnce daily · Week 1FDA-label starting dose for both Victoza (type 2 diabetes) and Saxenda (weight management); used for the first week to improve GI tolerability before escalation [6].
  • Ongoing1.2-1.8 mgOnce daily · OngoingVictoza maintenance range for type 2 diabetes; dose increased to 1.2 mg after week 1 and to 1.8 mg if further glycemic control is needed [6].
  • Ongoing3.0 mgOnce daily · OngoingSaxenda maintenance dose for chronic weight management, reached by escalating 0.6 mg weekly (0.6 to 1.2 to 1.8 to 2.4 to 3.0 mg over 5 weeks) [6].

Applications

Best suited for

Exenatide

Type 2 diabetes patients inadequately controlled on metformin seeking add-on therapy with weight loss benefit
Exenatide is particularly well-suited for individuals focused on type 2 diabetes patients inadequately controlled on metformin seeking add-on therapy with weight loss benefit. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
Patients preferring once-weekly dosing convenience (Bydureon 2 mg) over daily injections for improved adherence
Exenatide is particularly well-suited for individuals focused on patients preferring once-weekly dosing convenience (bydureon 2 mg) over daily injections for improved adherence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [7].
Overweight or obese type 2 diabetes patients (BMI >27) requiring glycemic control without weight gain
Exenatide is particularly well-suited for individuals focused on overweight or obese type 2 diabetes patients (bmi >27) requiring glycemic control without weight gain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [4].
Patients with established cardiovascular disease who need a GLP-1 RA with demonstrated cardiovascular safety
Exenatide is particularly well-suited for individuals focused on patients with established cardiovascular disease who need a glp-1 ra with demonstrated cardiovascular safety. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Liraglutide

Type 2 diabetes patients with HbA1c >7% requiring both glycemic control and weight management
Liraglutide is particularly well-suited for individuals focused on type 2 diabetes patients with hba1c >7% requiring both glycemic control and weight management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3].
Obese individuals (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities seeking FDA-approved pharmacotherapy
Liraglutide is particularly well-suited for individuals focused on obese individuals (bmi ≥30) or overweight (bmi ≥27) with weight-related comorbidities seeking fda-approved pharmacotherapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [6].
Patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy
Liraglutide is particularly well-suited for individuals focused on patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [7].
Patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile
Liraglutide is particularly well-suited for individuals focused on patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3].

Safety profile

Side effects

Exenatide

Common

  • Nausea
  • Vomiting and diarrhea
  • Injection site nodules (Bydureon)
  • Decreased appetite and constipation

Uncommon

  • Hypoglycemia

Serious

  • Acute pancreatitis
  • Renal impairment

Liraglutide

Common

  • Nausea
  • Diarrhea
  • Vomiting
  • Decreased appetite and headache

Uncommon

  • Injection site reactions

Serious

  • Acute pancreatitis
  • Gallbladder disease

Research status

Safety & evidence

Exenatide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Exenatide is an FDA-approved GLP-1 receptor agonist with post-market safety data spanning 15+ years, though some safety concerns have emerged. Nausea affects 30-45% of patients, [6] dose-dependent and typically improves within 1-2 weeks but can lead to treatment discontinuation in 5% of patients. Pancreatitis risk, while rare (0.1-0.2%), is increased and contraindicated in patients with history of acute pancreatitis. Benign thyroid C-cell adenomas were seen in rats across all exenatide doses in a 104-week carcinogenicity study, but this appears only in the Nonclinical Toxicology section: the immediate-release label (Byetta) carries no boxed warning and does not contraindicate medullary thyroid cancer or MEN 2. That contraindication belonged to extended-release Bydureon, which no longer has a current US label. Acute kidney injury has been reported in 0.3-1% of patients, particularly with concurrent NSAID or ACE inhibitor use. Hypoglycemia risk is minimal when used as monotherapy but increases substantially when combined with insulin or sulfonylureas.

Contraindications

  • Prior serious hypersensitivity reaction to exenatide or any excipient [6]
  • Extended-release exenatide only (Bydureon, now withdrawn in the US): personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. The immediate-release label carries no such contraindication and no boxed warning [6][7].

Liraglutide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Liraglutide (Victoza, Saxenda) is FDA-approved with extensive safety data from 15+ years of clinical use in diabetes (GLP-1 agonist) and obesity indications. Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of patients during dose escalation [6] but diminish significantly after 2-3 weeks of stable dosing. Black box warnings include risk of medullary thyroid carcinoma and pancreatitis, though absolute incidence remains rare. Injection site reactions are minimal. The compound shows no hepatotoxicity, nephrotoxicity, or major drug interactions at approved doses.

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC) — black box warning based on rodent thyroid C-cell tumor findings [6]
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [6]
  • Known hypersensitivity to liraglutide or any excipients [6]

Decision guide

Which is right for you?

Exenatide

Choose Exenatide if…

  • Type 2 diabetes patients inadequately controlled on metformin seeking add-on therapy with weight loss benefit
  • Patients preferring once-weekly dosing convenience (Bydureon 2 mg) over daily injections for improved adherence
  • Overweight or obese type 2 diabetes patients (BMI >27) requiring glycemic control without weight gain
  • Patients with established cardiovascular disease who need a GLP-1 RA with demonstrated cardiovascular safety

Liraglutide

Choose Liraglutide if…

  • Type 2 diabetes patients with HbA1c >7% requiring both glycemic control and weight management
  • Obese individuals (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities seeking FDA-approved pharmacotherapy
  • Patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy
  • Patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile